Heart Rhythm
Volume 6, Issue 9 , Pages 1297-1303 , September 2009

Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION® long QT syndrome genetic test

  • Jamie D. Kapplinger, BA

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota
    • ,
  • David J. Tester, BS

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota
    • ,
  • Benjamin A. Salisbury, PhD

      Affiliations

    • PGxHealth, LLC, a division of Clinical Data, Inc., New Haven, Connecticut
    • ,
  • Janet L. Carr, PhD

      Affiliations

    • PGxHealth, LLC, a division of Clinical Data, Inc., New Haven, Connecticut
    • ,
  • Carole Harris-Kerr, PhD

      Affiliations

    • PGxHealth, LLC, a division of Clinical Data, Inc., New Haven, Connecticut
    • ,
  • Guido D. Pollevick, PhD

      Affiliations

    • PGxHealth, LLC, a division of Clinical Data, Inc., New Haven, Connecticut
    • ,
  • Arthur A.M. Wilde, MD, PhD

      Affiliations

    • Department of Cardiology, Heart Failure Research Centre, Academic Medical Centre, Amsterdam, the Netherlands
    • ,
  • Michael J. Ackerman, MD, PhD

      Affiliations

    • Departments of Medicine, Pediatrics, and Molecular Pharmacology and Experimental Therapeutics/Divisions of Cardiovascular Diseases and Pediatric Cardiology, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. Michael J. Ackerman, Long QT Syndrome Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory, Guggenheim 501, Mayo Clinic, Rochester, Minnesota 55905

Received 17 February 2009 ,Accepted 23 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Kapplinger and Tester contributed equally to this work. Supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (Dr. Ackerman), and the Leducq Foundation, Grant 05 CVD, Alliance against Sudden Cardiac death (Dr. Wilde). Dr. Ackerman is a consultant for PGxHealth. Intellectual property derived from Dr. Ackerman's research program resulted in license agreements in 2004 between Mayo Clinic Health Solutions (formerly Mayo Medical Ventures) and PGxHealth (formerly Genaissance Pharmaceuticals).

PII: S1547-5271(09)00568-2

doi: 10.1016/j.hrthm.2009.05.021

Heart Rhythm
Volume 6, Issue 9 , Pages 1297-1303 , September 2009

Article Tools

* Image Usage & Resolution